Cardiorenal syndrome is defined by primary heart failure conditions influencing or 35 leading to renal injury or dysfunction. Dilated cardiomyopathy (DCM) is a major co-36 existing form of heart failure (HF) with renal diseases. Myocardin (MYOCD), a 37 cardiac-specific co-activator of serum response factor (SRF), is increased in DCM 38 mice and patient cardiac tissues and plays a crucial role in the pathophysiology of 39 DCM. Inhibiting the increased MYOCD has shown to be partially rescuing the DCM 40 mice phenotype. However, expression levels of MYOCD in the cardiac tissues of the 41 cardiorenal syndromic patients and the beneficial effect of inhibiting MYOCD in a 42 cardiorenal syndrome model remains to be explored. 43
MYOCD levels in the endomyocardial biopsies of DCM patients associated with renal 48 failure compared to DCM alone. Silencing of MYOCD in RAL rats by a cardiac 49 Introduction 56 DCM is a major cause of HF, 1 accounting for nearly 1/3rd of total cases. Many of 57 these patients subsequently display kidney dysfunction or injury leading to 58 cardiorenal syndrome. More than half of the heart failure patients show renal 59 diseases. Co-existence of cardiac and renal dysfunction in the patients increases the 60 mortality significantly compared to cardiac or renal disease alone patients. 61
Various molecular pathways including Renin-angiotensin-aldosterone system (RAAS) 62 are shown to be influencing the cardiorenal syndrome. Notably, circulating Ang II (an 63 essential component of RAAS) affects cardiac function by, increasing systemic 64 arteriolar vasoconstriction, vascular resistance, and cardiac afterload through AT1 65 receptor-mediated endothelial dysfunction 2 . 66
Ang II has been shown to induce MYOCD under hypoxic condition 3 . MYOCD is a 67 cardiac-specific transcriptional co-activator present in cardiomyocytes and smooth 68 muscle cells. MYOCD is involved in heart development and cardiomyocyte 69 differentiation 4,5 . Also, MYOCD is required for maintenance of structural integrity, 70 cardiomyocyte survival, and heart function 5-7 . Besides, cardiomyocytes and smooth 71 muscle cells MYOCD expression has been detected in fibroblasts 8 . MYOCD has 72 been shown to promote fibroblast to myofibroblast differentiation and to inhibit cell 73 proliferation 9 . Forced expression of MYOCD in fibroblasts induces cardio-myogenic 74
properties alone 8 and/or in combination with other factors 10 . Transforming growth 75 factor (TGF-β) was shown to induce MYOCD expression in fibroblasts and vice-76 versa 9 . TGF-β induction of MYOCD expression in the infarcted heart may have a 77 potential function in fibroblast-to-myofibroblast transition, similar to Myocardin related 78 transcription factor (MRTF)-A and MRTF-B which have been shown to be key 79 regulator in fibroblast to myofibroblast differentiation induced by TGF-β1 11 . Further, 80 deletion of MYOCD gene in the adult murine heart resulted in dilated 81 cardiomyopathy, and rapid death due to heart failure 5 . Upregulation of MYOCD 82 expression has been shown in cardiac hypertrophy 3,12,13 and MYOCD 83 overexpression in mouse cardiomyocytes resulted in activation of genes associated 84 with cardiac hypertrophy 12 . Increased cardiac MYOCD expression has been reported 85 in various cardiac ailments including DCM patients with end-stage HF 14,15 . MYOCD 86 has been shown to be a pro-hypertrophic factor in cardiac remodeling induced in 87 multiple models 3,12,13 . However, there is no report so far, suggesting the role of 88 MYOCD in cardiorenal syndrome. 89
In the present study, we analyzed the cardiac-specific expression of MYOCD in DCM 90 patients with renal disease and DCM alone cases. The results showed the MYOCD 91 is overexpressed in the DCM patients with renal disease compared to DCM alone 92 cases. In addition, the effects of cardiac-specific silencing of MYOCD was explored in 93 a cardiac renal syndrome rat model. The cardiac-specific silencing of MYOCD in rats 94 decreased the expression of upregulated hypertrophic and fibrotic genes leading to 95 restoration of left ventricular function. 
Cardiac specific silencing of MYOCD Gene 154
Cardiac MYOCD gene expression was inhibited in RAL rats using MYOCD specific 155 siRNA, conjugated with a cardiac specific 20mer homing peptide sequence 156 WLSEAGPVVTVRALRGTGSW encapsulated in stearic acid modified Carboxy 157 methyl chitosan as described earlier 18 , as per protocol shown in Supplementary 158 
MYOCD activation induces hypertrophic and fibroblast associated genes 246 247
To know the functional relevance of increase of MYOCD in cardiorenal patients, we 248 treated cardiomyocytes cells (H9c2) and fibroblasts with Ang II (a well-known 249 modulator of cardiorenal disease). The treatment showed increased mRNA and 250 protein expression of MYOCD in both cell types ( Supplementary Fig. 3a, 3b & 3c) , 251 along with hypertrophy markers including Atrial Natriuretic factor (ANP), Beta-Myosin 252 heavy chain (β-MHC) and fibrotic genes at mRNA levels such as Collagen (Col) 1a, 253
Col 3a, Col 4a, Transforming growth factor-β (TGF-β), Connective tissue growth 254 factor (CTGF) and Fibroblast growth factor (FGF)β respectively ( Fig. 2a, 2b & 2c) . 255
Pre-treatment with losartan (an Ang II type I receptor antagonist) reversed these 256 effects by increasing the levels of MYOCD, ANP and β -MHC mRNA levels in 257 cardiomyocytes, whereas, treatment with known Ang II analogue had no significant 258 effect on MYOCD, ANP and β -MHC expression in these cells ( Supplementary Fig.  259   3d) . 260 261
In vitro silencing of MYOCD inhibited Ang II induced cardiomyocyte 262 hypertrophy and fibrosis 263
To examine the effect of MYOCD silencing on cardiomyocyte hypertrophy, Ang II 264 treated H9c2 cells were transfected with MYOCD siRNA. siRNA transfection 265 significantly reduced the MYOCD levels ( Supplementary Figure 4a & 4b) , leading to 266 the reduction of ANP and β -MHC levels (Figure 3a & 3b) . 267
Also, treatment of MYOCD siRNA significantly decreased MYOCD mRNA expression 268 levels in the cardiac fibroblasts (Fig. 3c) , whereas scrambled siRNA also showed 269 some effect on MYOCD expression in these cells but the changes found in myocd 270 siRNA treated cells was much significant. MYOCD siRNA treated cells resulted in a 271 significant decrease in mRNA expression of Col 1a, Col 3a, Col 4a,TGF-β and FGF-β 272 genes in Ang II treated cardiac fibroblasts (Fig. 3d ). We found changes in CTGF 273 expression both with Ang II treatment and myocd siRNA but those changes were 274 non-significant. 275
Cardiac-specific inhibition of MYOCD gene in a cardiorenal rat model improves 276 left ventricular functions 277
To know whether MYOCD inhibition in a cardiorenal rat model can rescue the above 278 observed in vitro phenotype, we performed renal artery ligation (RAL) in rats. This 279 model has been shown to an excellent model for cardiac-renal heart failure 20 . RAL in 280 rats resulted in cardiac hypertrophy, fibrosis and systolic dysfunction ( Fig. 4a & 4b ; 281 Table 1) . 282
Next, we injected the MYOCD siRNA conjugated with homing peptide through tail 283 veins of the RAL rats as described earlier to be cardiac-specific and having no 284 bystander effects 18 . To study the effect of heart-specific MYOCD silencing on cardiac 285 function, echocardiography and HW/BW ratio were measured in MYOCD siRNA 286 treated RAL rats 15 days post ligation. HW/BW ratio was significantly reduced in 287 MYOCD siRNA treated RAL rats (Table 1) . A significant decrease in LVEDD and 288 increase in LVEF was also seen in these rats (Table 1) Ablation of MYOCD gene with MYOCD siRNA conjugated with homing peptide in 293 RAL rats resulted in significant reduction in cardiac MYOCD expression ( Fig. 4c & d) , 294 13 whereas scrambled siRNA did not affect the MYOCD expression. Also, a profound 295 reduction in the expression of hypertrophy markers, ANP and β -MHC ( Fig. 4c & d ) 296 and a decrease in cardiomyocyte size in MYOCD siRNA treated RAL rats compared 297 to untreated were noticed. (Fig. 4e III & IV) . There was no evidence of inflammation 298 or coronary occlusion in these rats, suggesting absence of ischemic lesions (Fig. 4e) . 299
The immuno-histochemical analysis also revealed reduction in cardiac MYOCD 300 ( Supplementary Fig. 5a -c) and β -MHC ( Supplementary Fig. 5d-f showed decreased collagen deposition in the treated RAL cardiac tissues (Fig. 5e ), 306 and reduced expression levels of fibrosis-related genes including Col 1a, Col 3a, Col 307 4a, CTGF, FGF-β and TGF-β. (Supplementary Fig. 5g-i) . Collectively, these data 308 suggested that the MYOCD inhibition can reverse the heart failure in RAL model. conjugated MYOCD siRNA to specifically inhibit cardiac MYOCD without any specific 337 bystander effects was employed 18 . We observed that this cardiac specific MYOCD 338 silencing resulted in attenuation of cardiomyocyte hypertrophy and cardiac fibrosis 339 when given at either both at pre-ligation or post-ligation stages. 340
Further, we compared whether siRNA inhibition was more effective at pre-or post-341 ligation to ascertain the efficacy of MYOCD inhibition on cardiac hypertrophy and 342 fibrosis under these two conditions. In pre-ligation treatment, MYOCD siRNA was 15 introduced before the initiation of cardiac remodeling process, and in post-ligation 344 treatment, MYOCD siRNA was given after the initiation of cardiac remodeling. Both 345 the treatment groups showed significant reduction in the cardiac remodeling and 346 improvement of cardiac function, but post-ligation treatment showed a greater 347 reduction. These results suggest that MYOCD inhibition is more effective at post 348 ligation stage, probably as MYOCD upregulation is maximal at this stage. 
